|Assessment Status||NCPE Assessment Process Complete|
|Indication||For the prevention of stroke and systemic embolism in atrial fibrillation|
|Full submission received from Applicant||02/11/2010|
|NCPE assessment completed||03/06/2011|
|NCPE assessment outcome||Reimbursement not recommended|
Following the NCPE pharmacoeconomic assessment (August 2011) the manufacturer reduced the price of dabigatran. At this revised price we now consider dabigatran cost effective for this indication.